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ABSTRACT
Introduction: Resistant hypertension is inadequately
controlled blood pressure (BP) despite treatment with
at least three BP-lowering drugs. A popular hypothesis
is that resistant hypertension is due to excessive
Na+-retention, and that ‘further diuretic therapy’ will be
superior to alternative add-on drugs.
Methods and analysis: Placebo-controlled, random
crossover study of fourth-line treatment when added to
standard (A+C+D) triple drug therapy: ACE inhibitor or
Angiotensin receptor blocker (A) +Calcium channel
blocker (C)+Diuretic (D). Patients (aged 18–79 years)
with clinical systolic BP≥140 mm Hg (135 mm Hg in
diabetics) and Home BP Monitoring (HBPM) systolic
BP average ≥130 mm Hg on treatment for at least
3 months with maximum tolerated doses of A+C+D are
randomised to four consecutive randomly allocated
12-week treatment cycles with an α-blocker, β-blocker,
spironolactone and placebo. The hierarchical coprimary
end point is the difference in HBPM average systolic
BP between (in order) spironolactone and placebo,
spironolactone and the average of the other two active
drugs, spironolactone and each of the other two drugs.
A key secondary outcome is to determine whether
plasma renin predicts the BP response to the different
drugs. A sample size of 346 (allowing 15% dropouts)
will confer 90% power to detect a 3 mm Hg HBPM
average systolic BP difference between any two drugs.
The study can also detect a 6 mm Hg difference in
HBPM average systolic BP between each patient’s best
and second-best drug predicted by tertile of plasma
renin.
Ethics and dissemination: The study was initiated
in May 2009 and results are expected in 2015. These
will provide RCT evidence to support future guideline
recommendations for optimal drug treatment of
resistant hypertension.
Trial registration number: Clinicaltrials.gov
NCT02369081, EUDract number: 2008-007149-30.
INTRODUCTION
Many patients treated for hypertension do
not achieve their target blood pressure,
deﬁned according to most guidelines as a
seated clinic blood pressure (BP) <140/
90 mm Hg. There are various reasons for
poor BP control, including clinical inertia in
up-titrating therapy and poor patient con-
cordance with treatment. There are also
patients who appear to be genuinely resistant
to drug treatment, hence the term ‘resistant
hypertension’.1 Resistant hypertension has
been deﬁned in various ways, but recent
international guidelines have moved towards
a consensus that resistant hypertension is
best deﬁned as poor BP control despite treat-
ment with at least three BP-lowering medica-
tions, one of which should be a diuretic.2 3
The recent National Institute for Health and
Care Excellence (NICE) guideline was even
more prescriptive by deﬁning resistant hyper-
tension as a blood pressure that is not
Strengths and limitations of this study
▪ Randomised, masked, adequately powered study
of rigorously defined resistant hypertension;
▪ Rigorously characterised population of patients
with resistant hypertension.
▪ Use of home blood pressure monitoring to
evaluate the blood pressure response to
treatment.
▪ The trial is not powered to detect the impact of
drug treatment on morbidity and mortality.
▪ Spironolactone is not licensed for the treatment
of hypertension in UK.
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controlled to recommended treatment targets despite
treatment with maximal recommended or best tolerated
doses of three speciﬁc drug types, that is, A+C+D,
according to the NICE hypertension treatment algo-
rithm, where ‘A’ is an ACE-inhibitor or Angiotensin
receptor blocker (ARB), ‘C’ is a Calcium channel
blocker (CCB) and ‘D’ is a thiazide/thiazide type diur-
etic.4 5 Thus, when referring to the drug treatment of
resistant hypertension, guidelines are speciﬁcally refer-
ring to fourth-line drug treatment, usually added to
treatment with A+C+D.
With regard to drug treatment of hypertension, a ‘rule
of thirds’ seems to apply, with approximately one-third
of hypertensive patients achieving BP control with a
single drug, one-third requiring two drugs and one-third
requiring three drugs or more. Some of those requiring
three drugs or more will be controlled with three drugs,
with most surveys suggesting that approximately 10% of
patients will require more than three drugs to control
BP, and thus are deﬁned as patients with resistant hyper-
tension.1 6 The true prevalence of resistant hypertension
has been poorly deﬁned, but based on the aforemen-
tioned assumptions the prevalence in the UK alone
would exceed 1 million people.
The choice of fourth-line drug treatment for resistant
hypertension has been entirely empirical. This reﬂects
the lack of data from randomised controlled trials dir-
ectly comparing different drug treatment options for
resistant hypertension; consequently, there remains real
clinical uncertainty about the preferred clinical manage-
ment of such patients. It is possible that it makes no dif-
ference what drug is added as fourth-line treatment and
that the response, on average, will be the same for all
available treatment options. Alternatively, it is possible
that one class of drug will usually be superior to all the
others because there is a common mechanism under-
pinning resistant hypertension for the majority of
patients. In this regard, a popular view is that resistant
hypertension is predominantly due to excessive sodium
retention and thus ‘further diuretic therapy’ will usually
be the most effective treatment.3 7 A third possibility is
that resistant hypertension is a more heterogeneous
state and that the study of average responses in cohorts
in clinical studies masks substantial individual patient
differences and that treatment decisions could poten-
tially be better stratiﬁed.
With regard to treatment stratiﬁcation, one approach
would be to use biomarkers of the patient’s sodium/
volume status, the rational being that an excess of total
body sodium would contribute to treatment resistance
and could help deﬁne the best treatment for patients
with resistant hypertension. In this regard, plasma renin
level is a surrogate for and inversely related to sodium
status.8 This may be especially true in patients already
receiving treatment with A+C+D, all of which would be
expected to increase plasma renin levels. In this setting,
we hypothesised that the ﬁnding of low plasma renin
(lowest tertile) would be strongly suggestive of excessive
sodium load as a mechanism for resistant hypertension
and thus, might predict that the best treatment response
would be obtained with further diuretic therapy as the
preferred fourth-line treatment. Conversely, the ﬁnding
of an elevated plasma renin (highest tertile) would
point to a better response to a drug that suppresses
plasma renin, that is, a β blocker, whereas those in the
mid-tertile of plasma renin would respond best to a
α-blocker as fourth-line treatment.
We selected spironolactone as the ‘further diuretic’
therapy to be tested because of observational data sug-
gesting its efﬁcacy in lowering BP in resistant hyperten-
sion.9–11 However, the downside with spironolactone is
the development of gynaecomastia in some patients with
prolonged usage.9 A previous crossover comparison of
diuretics showed that a potential alternative to spirono-
lactone in this setting is amiloride.12 Thus, PATHWAY-2
will obtain prospective, sequential comparative evidence
for amiloride in resistant hypertension by offering this
treatment as an open-label run-out to all patients after
completion of the prospective randomised treatment
cycles, at doses likely to have comparable efﬁcacy to the
doses of spironolactone. The PATHWAY 2 study was
initiated in May 2009, and the ﬁnal results are expected
in 2015. This manuscript describes the objectives, design
and respeciﬁed analysis plan for the PATHWAY 2 study.
METHODS
Study design
PATHWAY 2 is a randomised, double blind, placebo-
controlled, crossover, multicentre trial comparing the
four treatment options for patients with resistant hyper-
tension. The four treatment options are taken once daily,
in addition to the maximum/best tolerated doses of
three drugs at baseline according to the current NICE
hypertension treatment guideline, that is, A+C+D where:
A=ACE-inhibitor or Angiotensin receptor blocker;
C=Calcium channel blocker; D=thiazide/thiazide-type
Diuretic.4 5
After a screening visit, patients potentially eligible for
randomisation proceeded to a 4-week run-in period on
the patient’s baseline therapy with three drugs, that is,
A+C+D. After the run-in period and if still meeting the
eligibility criteria, the patients were allocated double
blind to a cycle of 4×once daily oral treatments in a
random sequence. The randomisation is not stratiﬁed
and in this 4 × 12-week period, four treatments crossover
study, participants are randomised with equal probability
to one of the 24 possible sequences of treatments. The
treatments comprise: (1) further diuretic therapy
—spironolactone; 25–50 mg, (2) α-blocker—doxazosin
modiﬁed release; 4–8 mg, (3) β-blocker—bisoprolol;
5–10 mg and (4) placebo. The treatment cycles were
initiated with each treatment for 6 weeks at the lower
dose, followed by forced titration to twice this dose for a
further 6 weeks—each cycle for a total of 12 weeks.
There is no washout period between the four treatment
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cycles (3 active, 1 placebo), as 12 weeks of treatment
per drug cycle is considered sufﬁcient to eliminate the
order effects of treatment. The total length of the trial is
52 weeks (4 weeks run-in and 4×12 week treatment cycles;
ﬁgure 1).
The trial was designed as double-blind, but this incurs
considerable extra costs; thus, we decided that the last
100 patients should be studied open-label, in order to
determine whether the large extra cost of blinding
confers any advantage. For the blinded phase of the
trial, the study drugs will be re-encapsulated to provide
participants with an identical single capsule throughout,
containing either active drug or placebo (microcrystal-
line cellulose). For the open label cohort, patients will
receive drugs according to the randomisation schedule
in the original drug manufacturers’ packaging.
Figure 1 PATHWAY 2 study
design and flow chart.
Williams B, et al. BMJ Open 2015;5:e008951. doi:10.1136/bmjopen-2015-008951 3
Open Access
group.bmj.com on September 2, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
During the double-blind phase, none of the investiga-
tors, patients or laboratory staff were aware of the assign-
ment. A 24-h telephone unblinding service was provided
by the Data Management Centre for instances where
principal investigators (PIs) believed that treatment of
an adverse event may be compromised by their not
knowing the treatment assignment.
Compliance has been assessed by returned tablet
counts.
Tolerability
Adverse events are recorded in the electronic case
record form at each visit. A 2-week drug holiday is per-
mitted at any point if the investigator considers that this
may allow participants to remain in the trial without
early withdrawal.
Run-out phase of the study
To evaluate if amiloride would be a suitable alternative to
spironolactone, the run-out phase of the study was used
to evaluate the BP-lowering effectiveness of amiloride
using an open label design. Patients were eligible for the
amiloride open label run-out phase of the study as long
as they did not develop potassium levels ≥5.5 mmol/L
during the study treatment cycles. If eligible, patients
were prescribed open-label amiloride 10 mg once daily
for 6 weeks, followed by forced titration to amiloride
20 mg once daily for a further 6 weeks. Patients were eval-
uated at study sites at 6 and 12 weeks, and BP recorded in
accordance with procedures for the main study. In the
remaining patients, physicians will choose the exit drug
based where possible on pretrial experience of fourth
and ﬁfth-line treatment. For patients with uncontrolled
BP at the end of the treatment cycles, or the amiloride
run-out phase, it was considered unethical to wait for
completion of the overall study before their best treat-
ment option could be revealed. Thus, at the end of the
main study, the data base will be locked for individual
patients and the data centre can reveal the best treatment
option for an individual patient at the request of the
study site PI. The full schedule of assessment and proce-
dures is shown in the table 1.
Special considerations
Early randomisation during the 4-week placebo run-in
phase, that is, 2 weeks, is allowed for safety reasons for
patients developing an excessively elevated BP >180/
110 mm Hg or if a fourth background drug has been dis-
continued at the screening visit or at the discretion of
the study site PI. A preplanned break of up to 3 months
from the study is permitted, providing patients have
completed the previous treatment cycle. A 2-week break
from study drugs is permitted to accommodate patients
with scheduling problems or for patients with adverse
events not deﬁnitely attributable to the study drugs.
Patients unable to tolerate a drug in a cycle are permit-
ted to move to the next drug in sequence. Extra study
visits after dose titration may be arranged at the discre-
tion of the study site PI.
Data handling and recording
Study data is recorded via remote data entry into a web-
based electronic case report form (eCRF) developed for
the study. The data will be collated and held at a single
study data management centre, the Robertson Centre
for Biostatistics (RCB) and Glasgow Clinical Trials Unit
(CTU). The eCRF data is anonymous and will identify
study participant by their assigned study numbers only.
Ethics approval and study registration
The PATHWAY 2 study has been approved by all relevant
ethics committees and all participants will sign informed
consent. Consent procedures will be undertaken by
trained nursing or clinical staff with delegated authority
of the local PI. The PATHWAY 2 study is registered with
clinicaltrials.gov; trial identiﬁer; NCT02369081 and
EUDract number: 2008-007149-30.
The initial protocol was approved by the Medicines
and Healthcare Products Regulatory Agency (MHRA)
on 14 January 2009, and is visible at https://www.
clinicaltrialsregister.eu/ctr-search/trial/2008-007149-30/
GB. It was approved by Cambridge Research Ethics
Committee on 12 January 2009. The trial was not regis-
tered with Clinicaltrials.gov until 2015 because of the
prior registrations with MHRA and UKCRN, and local
advice that these sufﬁced. The current version is 9,
dated 23 August 2012. Any further amendments will be
approved by Research Ethics and MHRA and also regis-
tered with clinicaltrials.gov.’
Study participants
The study will randomise 346 patients aged 18–79 years
from 14 study sites in the UK. These are the sites repre-
sented by the authors, plus Birmingham, Norwich,
Manchester, Ixworth and Exeter. Full addresses are at
clinicaltrials.gov. All patients will have uncontrolled BP,
that is, resistant hypertension despite treatment with
maximal/best tolerated doses of a combination of three
drugs, that is, A+C+D, according to the recommenda-
tions of the current NICE hypertension treatment guide-
lines.4 5 Uncontrolled BP is deﬁned as seated clinic
systolic BP ≥140 mm Hg for patients without diabetes or
≥135 mm Hg for patients with diabetes, based on a
mean of the last 2 of 3 consecutive clinic readings. In
addition, the HBPM systolic BP average must be
≥130 mm Hg and within 15 mm Hg of the clinic systolic
BP, in the 4 days prior to the baseline visit. Patients who
have received three drugs, that is, A+C+D, but are either
intolerant to one drug class or tolerate only a lower
dose, that is, submaximal recommended dose are eli-
gible. Patients receiving A+C+D and who are also receiv-
ing additional drugs for their hypertension may also be
included if the investigator (1) considers it is safe and
appropriate to stop these additional drug/s at the
screening visit and (2) anticipates that the BP criteria
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for inclusion will still be met after discontinuing the
drug/s when rechecked at the baseline visit. Patients can
also be included if the HBPM average systolic BP
exceeds 130 mm Hg during the run-in period.
Patients are excluded if their clinic systolic BP is
>200 mm Hg or diastolic BP >120 mm Hg, but the PI
has discretion to over-ride this criterion if home BP mea-
surements are lower. Patients were also excluded if they
had secondary or accelerated hypertension; type 1 dia-
betes (but not type 2 diabetes); an eGFR<45 mL/min or
a plasma potassium outside of normal range on two suc-
cessive measurements during screening, pregnancy,
while planning to conceive, or were women of childbear-
ing potential, that is, not using effective contraception;
had an anticipated change of medical status during the
trial (eg, surgical intervention requiring >2 weeks conva-
lescence); had an absolute contraindication to any of
the study drugs (eg, asthma) or a requirement for study
drug for reasons other than to treat hypertension (eg,
β-blockers for angina or diuretics other than those to
treat hypertension, or previous intolerance of the pro-
posed trial therapies, or had sustained atrial ﬁbrillation
or a recent (<6 months) cardiovascular event requiring
hospitalisation (eg, myocardial infarction or stroke)).
Patients were excluded if they were suspected of non-
adherence to antihypertensive treatment as determined
by a pill count at the end of the 4- week run-in period—
those with adherence <70% will be excluded from ran-
domisation, and those with a fall in home systolic BP to
<130 mm Hg, 6 h after witnessed administration of their
usual A+C+D therapy. A full list of inclusion and exclu-
sion criteria are shown in boxes 1 and 2.
Recruitment and randomisation of participants
Potentially suitable patients are identiﬁed from hospital
and general practice populations. Written informed
consent is obtained from participants by a medical inves-
tigator. The research nurse records baseline variables,
takes blood and urine for baseline biochemistry and
haematology, and records the medical history. Blood
samples are analysed at the local health service labora-
tory according to usual practice. Serum for future ana-
lyses and blood for future genetic analyses are stored by
centres. Participants who have given informed consent
and meet the inclusion and exclusion criteria at the end
of a month’s placebo run-in are randomised to receive
one of the possible sequences of the four trial treat-
ments, each in addition to any other antihypertensive
drug being taken at the time of randomisation. This is
performed by contacting a central computerised ran-
domisation facility based at the Robertson Centre for
Biostatistics, University of Glasgow, by telephone or via a
web-based service.
Study objectives and end-points
Primary objective
The primary study objective is to test the hypothesis that
the commonest cause of resistant hypertension is exces-
sive sodium retention, and that ‘further diuretic
therapy’, that is, spironolactone will be superior to other
potential ‘add-on drugs’ for people with resistant hyper-
tension, that is, inadequate BP control despite treatment
with maximal/best tolerated doses of the three drug
classes A+C+D, as recommended by the current NICE
treatment guidelines algorithm.
Secondary objectives
The main secondary objective is test the use of plasma
renin measurement to evaluate the ‘α, β, Δ’ rule8 for the
selection of the fourth-line drug for patients with drug
resistant hypertension—where α represents α-blockade,
β represents β-blockade and Δ represents ‘further diur-
etic therapy’. We propose that α-blockade will be the
most effective fouth-line treatment at lowering BP in
patients in the mid-tertile of plasma renin (expected to
be ≥20 mU/L but <100 mU/L); β-blockade will be the
most effective drug when the renin level in in the top
tertile (expected to be ≥100 mU/L) as this drug inhibits
renin secretion; further diuretic therapy with spironolac-
tone will be the most effective drug in the lowest tertile
of plasma renin (<20 mU/L), indicative of renin sup-
pression due to excessive sodium retention. Further sec-
ondary analyses will use physiological phenotyping of
non-invasive haemodynamic parameters indicative of
sodium retention and volume status, that is, cardiac
output, peripheral vascular resistance, bio-impedance,
pulse wave analysis and pulse wave velocity to evaluate
mechanisms for resistant hypertension and determine if
these methods can help better stratify the best treatment
for individual patients with resistant hypertension.
Box 1 PATHWAY 2 study inclusion criteria
1. Patients aged 18–79 years
2. Patients will all have hypertension that is not controlled to
target: clinic systolic BP ≥5 mm Hg above target (ie,
≥145 mm Hg for non-diabetic hypertensives or ≥135 mm Hg
for patients with diabetes), under one of the following
conditions:
A. Treatment for at least 3 months with lisinopril 20 mg
(A)+amlodipine 10 mg (C)+bendroflumethiazide 2.5 mg
(D) or their equivalents
B. Patients who have received the three drugs or equiva-
lents specified in (a), and are either intolerant to one
category, or tolerate only a lower dose (eg, amlodipine
5 mg or lisinopril 10 mg)
C. Patients receiving the three drugs or equivalents speci-
fied in (a), who are receiving additional drugs for their
hypertension, may be included if the investigator: (1)
feels it is appropriate to stop these additional drugs at
the screening visit and (2) anticipates that the BP cri-
teria for inclusion will be met when rechecked at the
baseline visit
3. Patients with a home systolic BP average of >130 mm Hg or
within 15 mm Hg of clinic BP over the 4 days prior to the
baseline visit.
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Study procedures
Clinic blood pressure measurement
Seated clinic blood pressure will be measured at each
clinic visit in accordance with the methods recom-
mended by the British Hypertension Society,13 using an
automated, approved and validated BP monitor
(Microlife Watch BP, Microlife) with an appropriate cuff
size applied to the non-dominant arm. Three measure-
ments will be recorded 1 min apart, after 5 min rest and
seated, and the average of the last 2 measurements will
be recorded as the clinic BP.
Home blood pressure monitoring
The HBPM systolic BP average will be used for the main
study end points. At several points during the trial,
HBPM readings will be recorded (immediately prior to
randomisation and at the end of 6 and 12 weeks of each
treatment cycle). BP will be measured using the non-
dominant arm, using the same BP monitor used for the
clinic BP measurement which will be issued to the
patient for use throughout the trial. BP readings will be
taken in the morning and in the evening, ideally at the
same times throughout the study, for example, ∼08:00
and 20:00—or the nearest time to these that is conveni-
ent for the patient. HBPM readings will be taken on
four consecutive days prior to a study visit. Participants
will be asked to make triplicate readings, 1 min apart,
after 5 min seated rest, and to record these on the pro
forma provided. All readings will also be captured auto-
matically by the monitor. For analysis, a maximum of the
last 18 recordings (ie, days 2–4, if all completed) will be
used. If the patient fails to comply with the recom-
mended number of recordings, a minimum of six BP
recordings is required for a valid measurement of the
HBPM average.
Plasma renin measurement
Plasma renin levels will be measured using a Diasorin
Liaison automated chemiluminescent immunoassay for
Box 2 PATHWAY 2 study exclusion criteria
Inability to give informed consent;
Participation in a clinical study involving an investigational drug or device within 4 weeks of screening;
Secondary or accelerated hypertension;
Type 1 diabetes;
eGFR<45 mL/min;
Plasma potassium outside of normal range on two successive measurements during screening;
Pregnancy, planning to conceive or women of childbearing potential, that is, not using effective contraception;
Anticipated change of medical status during the trial (eg, planned surgical intervention requiring >2 weeks convalescence);
Absolute contra-indication to study drugs (eg, asthma) or previous intolerance of trial therapy;
Sustained atrial fibrillation;
Recent (<6 months) cardiovascular event requiring hospitalisation (eg, myocardial infarction or stroke);
Suspected non-adherence to antihypertensive treatment (see above);
Requirement for study drug for reason other than to treat hypertension, (eg, β-blockers for angina or diuretics other than those to treat
hypertension);
Current therapy for cancer;
Concurrent chronic illness, or other reasons likely to preclude 52 week participation in the study;
Clinic Systolic BP >200 mm Hg or diastolic BP >120 mm Hg, with PI discretion to override if home BP measurements are lower
Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or
severely limit that patients life-span or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental
disorders);
Treatment with any of the following medications;
Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study participation;
▸ Chronic stable use, or unstable use of NSAIDs (other than low dose aspirin) is prohibited. Chronic use is defined as >3 consecutive or
non-consecutive days of treatment per week. In addition intermittent use of NSAIDs is strongly discouraged throughout the study and
NSAIDs if required, must not be used for more than a total of 2 days. For those requiring analgesics during the study, paracetamol is
recommended.
▸ The use of short-acting nitrates (eg, sublingual nitroglycerin) is permitted. However, participants should not take short acting oral nitrates
within 4 h of screening or an subsequent visit;
▸ The use of long-acting nitrates (eg, Isordil) is permitted but the dose must be stable for at least 2 weeks prior to screening and
randomisation;
▸ The use of sympathomimetic decongestants is permitted, however, not within 1 day prior to any study visit/BP assessment;
▸ The use of theophylline is permitted but the dose must be stable for at least 4 weeks prior to screening and throughout the study;
▸ The use of phosphodiesterase type V inhibitors is permitted; however study participants must refrain from taking these medications for
at least 1 day prior to screening or any subsequent study visits;
▸ The use of α-blockers is not permitted, with the exception of afluzosin and tamsulosin for prostatic symptoms
A pill count will be made at the end of the 4 week run-in period and those with adherence <70% will be excluded from randomisation
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direct renin. Performed in Cambridge (English centres)
and Edinburgh (Scottish centres).
Assessment of drug treatment compliance
It is recognised that poor concordance with drug treat-
ment contributes to apparent drug treatment resistance.
Robust checks for treatment concordance are included
in the study procedures: (1) At baseline and as a pre-
requisite for randomisation, patients will be witnessed
consuming their usual BP medications (A+C+D) in the
clinic and then HBPM will be performed over the next
6 h to conﬁrm that their BP is not controlled with their
usual treatment; (2) Tablet counts will be performed at
baseline (end of placebo run-in) and after 12 weeks of
each treatment cycle, and patients with less than 70%
tablet consumption will be deemed non-concordant
with their medication; (3) Serum ACE levels will be mea-
sured to provide a retrospective measure of treatment
concordance; (4) Urine samples will be stored frozen at
−20°C at selected sites throughout the study, for analysis
of urinary drug metabolites at a single site (University of
Leicester) using high-performance liquid chromatog-
raphy/mass spectroscopy to provide a retrospective ana-
lysis of treatment concordance with individual drugs.14
Non-invasive phenotypic profiling of haemodynamics and
volume status
Non-invasive haemodynamic measures (cardiac output,
peripheral resistance, bioimpedance) using thoracic
bioimpedance cardiography (Cardiodynamics USA) and
pulse wave analysis and pulse wave velocity measure-
ments (Sphymocor, Australia, or equivalent) will be
recorded at baseline and at the end of each treatment
cycle at selected study sites.
Pharmacogenetics
Blood samples will be taken at baseline and the DNA
extracted and stored for pharmacogenetic analysis. At
the end of the study, these samples will be transferred
from each site to Cambridge.
Safety assessments
All observed or volunteered adverse events considered
related to treatment will be recorded on the adverse
events section of the eCRF. Study staff will pursue and
obtain information to conﬁrm whether the event meets
the criteria for classiﬁcation as a serious adverse event.
An event will be deemed serious if it results in death, is
life-threatening, requires hospitalisation, results in per-
sistent or signiﬁcant disability/incapacity, is a congenital
anomaly or birth defect, or is another medically import-
ant event. Adverse events will be classiﬁed according to
seriousness, severity (mild, moderate or severe), causal
relationship (certain, probably, possible, unlikely, unre-
lated) and expectedness. Suspected unexpected serious
adverse drug reactions (SUSAR’s) are not considered
likely in this trial as there have been many years of
experience with each of the trial drugs. All potential
SUSAR’s are subject to expedited reporting. Evaluations
of blood pressure, blood counts, blood chemistry, urin-
alysis, ECGs, physical examination and monitoring of
vital signs are scheduled to be performed at regular
intervals and can be increased in frequency if required,
at the discretion of the PI.
Data handling and record keeping
Study data is recorded by remote data entry into a web-
based electronic case report form (eCRF) developed for
the study by the Robertson Centre, Glasgow. eCRF data
is anonymous and will identify study participants by their
assigned study numbers only. All missing data, possible
duplication and data outside preset limits for each par-
ameter is queried by the Management Centre, and will
be internally validated before database lock.
Statistical analysis plan
The study has a hierarchical coprimary end point which
will be the difference in the home systolic BP between
spironolactone and placebo, followed by the difference
in home systolic BP between spironolactone and the
average of the other two active drugs, (doxazosin and
bisoprolol), followed by the difference in home systolic
BP between spironolactone and each of the other two
active drugs. For secondary analyses, similar analyses of
the primary analysis will be made using clinic blood
pressure. We will also compare the proportion of
patients achieving target blood pressure (home and/or
clinic) with each of the three active treatments. We will
examine the proportion of patients controlled by each
drug who are also controlled by the run-out treatment,
amiloride. We will look at the direction of correlation
between plasma renin and the blood pressure response
to each drug. We will then describe differences between
blood pressure response to each drug at extremes of
plasma renin. Similar analyses will be performed for
each haemodynamic variable. We will also examine the
predictive value of the baseline measurements of cardiac
output, systemic vascular resistance and thoracic imped-
ance. The study will also explore the cost-beneﬁt of
using plasma renin to stratify best treatment in individ-
ual patients. An additional end point will be analyses of
relationships between genetic factors and pharmacody-
namic responses.
Sample size calculation
The sample size was based on detecting a difference of
3 mm Hg (SD=12 mm Hg) in systolic blood pressure
between each of the experimental drugs and the
placebo treatment with 90% power, and using a single
sample t test at the 0.003 signiﬁcance level (0.01 level
adjusted for 3 comparisons being made). Variances in
these calculations were estimated from the within-subject
(interdrug) variability observed in 90 patients participat-
ing in the Cambridge crossover studies of the major
drug classes.
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The estimated requirement was for 294 patients; so we
set a recruitment target of 346 to allowing for a dropout
rate of 15%. This number also provides similar power to
detect a twofold increase in superiority through renin
proﬁling, namely a 6 mm Hg difference in systolic BP
between best and second-best drug within each quartile
of plasma renin.
Statistical model
The protocol requires patients to take triplicate morning
and evening HBPM BP readings for the 4 days before
each study visit, a total of 24 readings per visit. We shall
use the arithmetic mean of last 18 measurements prior
to a study visit to calculate home blood pressure. If more
than 18 measurements have been obtained, the earliest
recorded readings will be discarded. Thus, for most
patients we will use all the readings on days 1 to 3 prior
to the visit, but if any of these are missing then readings
from day 4 will be used instead. The minimum number
of measurements required for a valid assessment of
home blood pressure using home BPM is six. Means of
the morning and evening readings will be used in all
subsequent analysis.
We shall use a mixed model to analyse HBPM BP, with
unstructured covariances for the repeated measures for a
patient. The model will include terms for time of day
(morning or evening), gender, age, height, weight and
smoking history. We will also adjust for baseline BP. If any
of the baseline BPs cannot be estimated, we will substitute
the overall mean baseline value, set an indicator variable
to denote an imputed value and include the indicator
variable in the model. The model will also include terms
for treatment and phase (to allow for period effects), and
an indicator variable to identify the subgroup of patients
whose crossover treatments were unblinded.
The primary analysis will use BPs recorded for the
maximum tolerated dose of each drug. The ﬁrst of the
primary end points is the mean difference between spir-
onolactone and placebo; the second is the mean differ-
ence between spironolactone and the average of other
active treatments; and the third and fourth are the
mean differences between spironolactone and each of
the other active treatments taken individually.
The secondary analysis will estimate for each treatment:
changes in home BP; clinic BP on maximum tolerated
dose, and changes in clinic BP; responder rates; withdra-
wals due to adverse events; and haemodynamic variables
and pulse wave analyses. We shall use mixed models to
analyse the continuous variables and these will include
baseline covariates.
A patient will be deemed a “responder’ if they meet
any of these two conditions; (1) HBPM systolic BP
(SBP) <135 mm Hg; (2) HBPM SBP has fallen
≥10 mm Hg since baseline. Responder rates will be ana-
lysed by logistic regression and will be adjusted for base-
line covariates. Withdrawal rates will be analysed by
logistic regression and will be adjusted for baseline
covariates.
The main secondary objective is to use plasma renin
measurements to evaluate an ‘α, β, Δ’ rule for the selec-
tion of the fourth-line drug for patients with drug-
resistant hypertension (see secondary objectives above).
The hypothesis is that plasma renin (measured on a back-
ground of 3 drugs, ie, A+C+D), will predict the most
effective fourth-line drug. We shall identify the best treat-
ment for each patient, that is, the one on which they
achieved the lowest BP. This is a categorical response and
Figure 2 Predicted probabilities model for plasma renin as the predictor of the best treatment option for resistant hypertension.
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we shall use a logistic model to estimate the probability
of each treatment being declared the best as a function
of baseline renin. Superimposed plots of these probabil-
ities (see ﬁgure 2) will show the range of renin values
for which each treatment is most likely to be the best
choice. We will also, in the same way, evaluate haemo-
dynamic parameters indicative of sodium retention and
volume status, that is, cardiac output, peripheral resist-
ance and bioimpedance as predictors of the best fourth-
line treatment among the three active treatments. An
additional end point will be analyses of relationships
between genetic factors and pharmacodynamic
responses.
Blinded versus unblinded cohorts
We will assess the advantage and disadvantages of using
the double-blind, placebo-controlled random crossover
design in comparison to the open label random cross-
over design. We will expand the models used to analyse
the primary and secondary outcomes to estimate a
cohort effect (unblinded vs blinded) within each
treatment.
Patients who withdraw from the study before ﬁnal visit
will be included in the primary analysis if they have at
least one postrandomisation HBPM, and missing data
imputed by application of the last observation carried
forward. Patients with data missing from any time point
required for analysis, and patients in whom major viola-
tion of the protocol is documented by investigators or
detected by the data management centre will be
excluded from per-protocol analysis.
There will be no interim analysis, no stopping rules
and no data monitoring committee. This is because all
treatments are being used for licensed indications, and
have been so used for several decades. We do not, there-
fore, anticipate any unexpected hazard that has eluded
detection during many millions of person-years expos-
ure, and the study is not powered to detect any signiﬁ-
cant differences in serious morbidity or mortality
between treatment groups.
Ethics and dissemination
PATHWAY-2 is approved by Cambridge South Ethics
Committee and the MHRA. The results will be pub-
lished in a peer-reviewed journal, and presented at
national and international meetings. All authors of this
article will have full access to the complete data set,
subject only to agreement by coauthors to uses of the
data. Authorship of future articles reporting outcomes
will represent multidisciplinary input at each site, with
the articles being written by a subset of the current
authorship. There are no current plans to make anon-
ymised participant-level data publicly available. However,
lay-friendly summaries of our ﬁndings will be sent to all
our patients, and we expect to work with the British
Heart Foundation to maximise patient and public access
to the ﬁndings.
Ancillary and post-trial care
During the trial, all patients are covered by the NHS
indemnity. We expect most patients to continue the
most effective trial treatment, in addition to other pre-
trial background therapy that has been continued
during the trial.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The trial is sponsored by the University of Cambridge
and Cambridge University Hospitals NHS Foundation
Trust, contact stephen.kelleher@addenbrookes.nhs.uk.
Trial investigators will permit authorised third parties
access to the trial site and medical records relating to
trial participants. This will include, but not necessarily
be restricted to, access for trial-related monitoring,
audits, Ethics Committee review and regulatory inspec-
tions. We do not expect funders or sponsors to be
involved in data analysis or reporting.
Associated projects
This study (PATHWAY-2) is one of three complementary
studies in a BHF-funded programme which will investi-
gate optimal treatment for patients with hypertension.
PATHWAY-115 will investigate whether initial treatment
with a combination of drugs is more effective in achiev-
ing a sustained target pressure than starting with mono-
therapy and adding a second drug. PATHWAY-316 will
assess the impact of thiazide diuretic versus a combin-
ation of thiazide diuretic and potassium-sparing diuretic
on glucose tolerance and BP lowering efﬁcacy.
Access to the clinical trial data
There are no contractual agreements in place that limit
free access to the clinical trial data for the study investi-
gators or any other future collaborators.
Study oversight and management
The study executive committee
The study executive committee comprises Professors
Morris Brown, Tom MacDonald and Bryan Williams. The
executive committee will be responsible for high-level
decisions affecting the running of the trial (eg, closure of
study sites, response to emerging safety issues), and will
convene quarterly or more frequently, as required.
The study steering committee
The study steering committee comprises the Executive
Committee and other PI, the study coordinator and
representatives from the Data Monitoring Centre. The
steering committee will be responsible for setting up,
evaluating and reporting the results of the trial. The
Steering Committee will convene on an annual basis or
more frequently, as required.
Williams B, et al. BMJ Open 2015;5:e008951. doi:10.1136/bmjopen-2015-008951 9
Open Access
group.bmj.com on September 2, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
DISCUSSION
The PATHWAY 2 study is the ﬁrst RCT comparing differ-
ent drug treatment options in a well-characterised popu-
lation of patients with resistant hypertension. The study
will deﬁne whether a speciﬁc type of drug is usually
dominant with regard to BP lowering efﬁcacy, or
whether the response to treatment is more heterogen-
ous. The PATHWAY 2 study also includes assessments of
plasma renin and detailed cardiovascular physiological
phenotpying, which will provide important insights into
underlying mechanisms for resistant hypertension and
help determine whether treatment decisions could be
better stratiﬁed using measurements such as plasma
renin. In the absence of any prior RCTs of this type, the
data provided by this study will undoubtedly inﬂuence
future treatment guidelines for the treatment of resistant
hypertension.
The PATHWAY 2 study forms part of a trilogy of studies
(PATHWAY 1,2,3)15 16 currently being undertaken by the
British Hypertension Society research network that have
been speciﬁcally designed by clinical researchers, who
are leading regional specialist hypertension clinical ser-
vices, to tackle fundamental unresolved questions regard-
ing the treatment of hypertension. The need for clinical
trial data to inform future recommendations for the treat-
ment of resistant hypertension was also highlighted by
NICE as a key research question.5
Challenges in studying resistant hypertension
In the past, studies of resistant hypertension have been
difﬁcult because of a lack of consensus with regard to the
deﬁnition of resistant hypertension and the need to
exclude a variety of factors that can lead to apparent or
pseudo-resistant hypertension, including (1) poor BP
measurement techniques and failure to exclude a so
called ‘white coat effect’ in which the clinic BP is elevated
despite multiple drug treatments, but BP measured using
ambulatory or home BP measurements shows BP to be
controlled;17 (2) failure to exclude underlying and
potentially remediable secondary causes of hypertension,
such as aldosterone producing adenomas, renovascular
disease, phaeochromocytoma, etc and (3) poor recogni-
tion of the scale of non-partial or partial patient concord-
ance with their drug therapy.1 14 Furthermore, there has
been a longstanding lack of enthusiasm by the big
pharmaceutical companies for drug development and
clinical trials in this area, in part due to an aversion to
developing drug new therapies that would only be used
as a fourth-line treatment, as well as the aforementioned
lack of consensus regarding the deﬁnition of resistant
hypertension and a clear understanding of the under-
lying pathophysiological mechanisms. That said, the
recent emergence device-based therapies that have spe-
ciﬁcally targeted resistant hypertension have served to
elevate the proﬁle of resistant hypertension and have also
underscored the challenges and complexity in identify-
ing, characterising and studying these patients.18 19
International context for the study
The PATHWAY 2 study has beneﬁted from an emerging
international consensus regarding the deﬁnition of
resistant hypertension,2 3 which is consistent with the
deﬁnition used in our study, based on NICE guide-
lines.4 5 Moreover, all current international guidelines
have recently converged and now recommend A+C+D as
the preferred three-drug combination at step 3 of their
treatment algorithms, which forms the basis of the diag-
nosis of resistant hypertension.2–4 20–22 This means that
the ﬁndings of our study will have broad international
relevance and applicability. Our study also beneﬁts from
inclusion of robust methods to monitor treatment con-
cordance and the inclusion of home blood pressure
monitoring to exclude a ‘white coat effect’ and provide
a more comprehensive assessment of the BP response to
the various treatments. In addition, most of our study
sites are specialist hypertension centres, ensuring that
potential secondary causes for resistant hypertension will
have been excluded. Taken together with the renin pro-
ﬁling and detailed physiological phenotyping, the
PATHWAY 2 study will be recruiting the most precisely
deﬁned resistant-hypertension population to date.
Choice of drug therapies to be tested
When designing the PATHWAY 2 trial, the potential
drug treatment options to be tested were limited by the
fact that most patients will already have been treated
with A+C+D at baseline. Thus, the potential fourth-line
drugs to be tested included further diuretic therapy and
sympathetic nervous system (SNS) blockade with either
α-blockade or β-blockade. We considered other possible
treatments, such as centrally acting drugs, but as these
predominantly act through modulation of the SNS, the
use of α-blockade or β-blockade would allow us to test
whether increased activity of the SNS is a key underlying
mechanism for resistant hypertension. This has become
even more relevant with the emergence of device-based
treatment strategies, such as renal denervation, which
are designed to target the SNS.18 The choice of spirono-
lactone as ‘further diuretic’ therapy for our study was
supported by data, predominantly from observational
studies, suggesting that this treatment may be particu-
larly effective in patients with resistant hypertension.9–11
This decision was subsequently supported by the NICE
guideline recommendation in 2011, which noted that
the best available data supported the use of low dose
spironolactone for the treatment of resistant hyperten-
sion, but noted the absence of RCTs to test this hypoth-
esis and recommended that RCTs were required to
better deﬁne optimal treatment for resistant hyperten-
sion.4 5 The testing of an α-blocker as treatment for
resistant hypertension was supported by observational
data, albeit on a background of two rather than three
drugs, suggesting that an α-blocker could be an effective
add-on therapy.23 The choice of a β-blocker was also
logical because in addition to providing an alternative
mechanism to inhibit the SNS, β-blockade also
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Table 1 PATHWAY 2 Study schedule and procedures
Screening Randomisation Phase 1 Phase 2 Phase 3 Phase 4
Week −4 Week 0 Week 6 Week 12 Week 18 Week 24 Week 30 Week 36 Week 42 Week 48
Informed consent X
Medical history X X X
Clinical examination X X
Concomitant medications X X X X X X X X X X
Weight X X X X X X X X X X
Inclusion/exclusion criteria check X X
Clinic BP and heart rate X X X X X X X X X X
Home BP and heart rate* X X X X X X X X X
Home BP 6 h after witnessed administration of A+C+D
medication†
X
12 lead ECG X X
PEFR X X X X X X X X X X
Blood tests—electrolytes, urea, creatinine X X X X X X X X X X
Blood tests—glucose, lipids, uric acid, Ca++ X X
Blood tests—cholesterol, HDL and triglycerides X X
Blood tests –plasma renin/aldosterone‡ X
Pharmacogenetics§ X
Blood tests—haematology, albumin, glucose X X X X X
Blood—serum ace levels X
24 h urinary electrolytes X
Urinalysis X X X X X X
HCG testing pregnancy X X X X X
Haemodynamic measures (cardiac output, peripheral
resistance, bioimpedance), pulse wave analysis/velocity¶
X X X X X
Compliance check X X X X X X X X X
Directly observed therapy X
AE reporting X X X X X X X X
Randomisation X
Dispensing X X X X X X X X X X
*Home BP measurements are recorded twice daily in triplicate in the 4 days leading up to the baseline visit and week 6 and week 12 visits of each treatment cycle.
†To exclude white coat hypertension and confirm adherence.
‡In the event that plasma renin/aldosterone is not taken at baseline, it will be measured at week 12 of each treatment cycle.
§Pharmacogenetics sample to be taken where specific informed consent has been given. Sampling will typically be at baseline (day 0) but may be at any time later in the study.
¶Where equipment is available.
AE, adverse events; BP, blood pressure; HCG, human chorionic gonadotropin; HDL, high-density lipoprotein; PEFR, peak expiratory flow rate.
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suppresses plasma renin and thus allows our ‘α, β, Δ’
rule and plasma renin hypothesis to be tested (see
below), which states that a β-blocker would be the most
effective treatment when plasma renin is elevated at
baseline.
Evaluating strategies for treatment stratification
The PATHWAY 2 study also incorporates measurement
of plasma renin and a detailed physiological evaluation
of patients with resistant hypertension (eg, cardiac
output, systemic vascular resistance, arterial stiffness and
thoracic bioimpedance) to determine if these tests can
better predict the best response to a speciﬁc drug type.
The principal secondary hypothesis tests an ‘α, β, Δ’
rule8 which states that (1) further diuretic therapy (Δ),
that is, spironolactone, will be the best therapy in
patients with evidence of sodium and volume overload,
and this will be predicted by a low plasma renin at base-
line, despite treatment with A+C+D; (2) that a β-blocker
(β), that is, bisoprolol, which suppresses renin would be
the best treatment in patients with a high plasma renin
at baseline; and (3) that an α-blocker (α), that is, doxa-
zosin, would be the best treatment in those with a
plasma renin level in the mid-tertile. Such a ﬁnding
would suggest potential utility in measuring plasma
renin to stratify the most appropriate treatment for indi-
vidual patients. This concept was suggested many years
ago24 and previous studies have suggested that physio-
logical phenotyping of sodium/volume status (for which
plasma renin is a surrogate) have suggested that this can
predict the most effective treatment.25 In this regard,
our primary hypothesis states that we expect the most
common underlying pathophysiology for resistant hyper-
tension will be sodium/volume overload, resulting in a
low plasma renin at baseline, and consequently the best
response will be obtained with further diuretic therapy,
that is, spironolactone, in most patients.
Evaluating further diuretic therapy
Since spironolactone has been associated with the devel-
opment of gynaecomastia, estimated to occur in approxi-
mately 6% of patients,9 we also incorporated an open
label run-out phase for the study during which patients
will be treated with amiloride, a potassium-sparing diur-
etic, to determine if this replicates the effects of spirono-
lactone on BP, thus providing an alternative further
diuretic therapy for those intolerant of spironolactone.
Differential BP thresholds for patients with
and without diabetes
When this study was designed in 2008, international
guidelines had recommended differential BP threshold
and targets for people with and without diabetes. Thus,
a clinic systolic BP threshold of ≥140 mm Hg was
adopted for the deﬁnition of uncontrolled BP despite
treatment with A+C+D for people without diabetes and
≥130 mm Hg for those with diabetes, with the goal of
achieving systolic BP levels below these values. Recent
guidelines have adopted a more conservative systolic BP
threshold of ≥140 mm Hg for people with diabetes;2 19
however, because our study was already well underway by
then, we decided not to adjust our inclusion criteria for
people with diabetes.
Double blind versus open label design for the
treatment cycles
We designed this study as a double blind study for the
treatment cycles, with active study drugs and placebo
being identically encapsulated for blinding. The costs
and logistics of doing this are substantial and as patients
were destined to receive all treatments in random rota-
tion, we questioned the value of the blinding process as
the trial progressed. We decided to evaluate the import-
ance of blinding the treatment allocations by adopting
an open label design for the ﬁnal 100 patients recruited
into the trial by dispensing the active treatments in their
usual packaging. We will conduct analyses to determine
if this had any impact on the outcome in the blinded
versus unblinded phases of the trial. These ﬁndings will
provide valuable information with regard to the neces-
sity of the expensive treatment blinding procedures for
future studies of this kind.
CONCLUSIONS
The PATHWAY 2 trial is fully recruited and is due to
complete in 2015. The dropout rate is within expecta-
tions and thus, the trial should be fully powered to test
its primary and secondary hypotheses. PATHWAY 2 is the
ﬁrst robust RCT to evaluate the optimal treatment/s for
resistant hypertension and will deﬁne whether treatment
can be best stratiﬁed according to plasma renin levels.
Whatever the outcome, the ﬁndings of PATHWAY 2 are
likely to inﬂuence future international guidelines for the
drug treatment of resistant hypertension and provide
insights into underlying mechanisms that could facilitate
the targeted development of new therapies for this
condition.
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